The role of IL-6/JAK2/STAT3 signaling pathway in cancers

Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation. It can activate janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) signaling pathway. As one of the important signal transduction pathways in cells, JAK2/STAT3 signaling pathway plays a critic...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 1023177
Main Authors Huang, Bei, Lang, Xiaoling, Li, Xihong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 16.12.2022
Subjects
breast cancer
colorectal cancer
gastric cancer
IL-6/JAK2/STAT3 signaling pathway
liver cancer
lung cancer
Oncology
lung cancer
pancreatic cancer
colorectal cancer
gastric cancer
ovarian cancer
breast cancer
IL-6/JAK2/STAT3 signaling pathway
liver cancer
Online AccessGet full text
ISSN2234-943X
2234-943X
DOI10.3389/fonc.2022.1023177

Cover

More Information
Summary:Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation. It can activate janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) signaling pathway. As one of the important signal transduction pathways in cells, JAK2/STAT3 signaling pathway plays a critical role in cell proliferation and differentiation by affecting the activation state of downstream effector molecules. The activation of JAK2/STAT3 signaling pathway is involved in tumorigenesis and development. It contributes to the formation of tumor inflammatory microenvironment and is closely related to the occurrence and development of many human tumors. This article focuses on the relationship between IL-6/JAK2/STAT3 signaling pathway and liver cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, pancreatic cancer and ovarian cancer, hoping to provide references for the research of cancer treatment targeting key molecules in IL-6/JAK2/STAT3 signaling pathway.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Yi-Jia Li, Beckman Research Institute, City of Hope, United States; Ravi Manoharan, University of Madras, India; Larissa Menezes dos Reis, State University of Campinas, Brazil
Edited by: Maria Felice Brizzi, University of Turin, Italy
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.1023177